Karolina Dorosz

Ms. Karolina Dorosz

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2025 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
Lidia MajewskaLidia Majewska
Lidia Majewska
KDKarolina Dorosz
Karolina Dorosz
JKJacek Kijowski
Jacek Kijowski
Objective: To present and analyze eight clinical cases illustrating the use of rose stem cell‐derived exosomes (RSCEs) in treating various dermatological conditions and to review current literature on plant‐derived exosomes in medicine and dermatology. Background: RSCEs possess low cytotoxicity, high biocompatibility, and effective cellular uptake, making them promising agents for dermatological therapies. A literature review included in the introduction and discussion covers the broader role of plant‐derived exosomes, highlighting their therapeutic potential in skin treatment. Methods: A case‐by‐case analysis was conducted on eight patients with conditions including atopic dermatitis (AD), hyperpigmentation, scarring, wounds, melasma, and antiaging concerns. Each case provided insights into RSCEs' efficacy, with a focus on their antioxidant and anti‐inflammatory properties, as well as specific learning points derived from clinical observations. Results: The cases demonstrated RSCEs' multifaceted therapeutic effects across different skin conditions, supporting their role in enhancing skin regeneration, wound healing, and reducing hyperpigmentation and scarring. The literature review underscored RSCEs' unique bioactivity, suggesting mechanisms for their observed effects, including anti‐inflammatory and rejuvenating properties, which contributed to favorable clinical outcomes. Conclusion: RSCEs show potential as a valuable treatment in dermatology, as evidenced by the positive results across multiple skin conditions and their alignment with existing literature on plant‐derived exosomes. This case series emphasizes the need for further randomized and controlled clinical trials to confirm these preliminary findings and expand RSCEs' clinical application in dermatology.

14 July 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Lidia MajewskaLidia Majewska
Lidia Majewska
AKAgnieszka Kondraciuk
Agnieszka Kondraciuk
KDKarolina Dorosz
Karolina Dorosz
ABAgnieszka Budzyńska
Agnieszka Budzyńska
Background: Scar formation and impaired wound healing represent significant challenges in dermatology and aesthetic medicine, with limited effective treatment options currently available. Objectives: To evaluate the efficacy and long-term outcomes of Damask rose stem-cell-derived exosome (RSCE) therapy in the management of diverse dermatological conditions, including traumatic wounds, surgical scars, and atrophic acne scars. Methods: We conducted a case series study from June 2023 to November 2024, documenting four cases with different types of skin damage treated with lyophilized RSCE products. Treatment protocols included a variety of delivery methods such as topical application, microneedling, and post-procedure care. Follow-up assessments were performed at intervals ranging from 7 days to 10 months. Results: All patients demonstrated significant improvements in scar appearance, skin elasticity, hydration, and overall tissue quality. In traumatic facial injury, RSCE therapy facilitated reduction in scar contracture and improved functional outcomes. For atrophic acne scars, comparative treatment of facial sides showed enhanced results with RSCE addition. Acute wounds exhibited accelerated healing with reduced inflammation, while chronic wounds demonstrated improved epithelialization and long-term scar quality. Conclusions: This case series provides preliminary evidence suggesting that RSCE therapy may offer significant benefits in wound healing and scar management. The observed improvements in tissue regeneration, inflammatory modulation, and long-term aesthetic outcomes warrant further investigation through controlled clinical trials.

25 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Lidia MajewskaLidia Majewska
Lidia Majewska
AKAgnieszka Kondraciuk
Agnieszka Kondraciuk
IPIwona Urszula Paciepnik
Iwona Urszula Paciepnik
ABAgnieszka Budzyńska
Agnieszka Budzyńska
KDKarolina Dorosz
Karolina Dorosz
Background: Wound healing and scar management remain significant challenges in dermatology and aesthetic medicine. Recent advances in regenerative medicine have introduced plant-derived exosome-like nanoparticles (PDENs) as potential therapeutic agents due to their bioactive properties. This study examines the clinical application of rose stem cell exosomes (RSCEs) in combination with established treatments for managing different types of scars. Methods: A case series of four patients with different scar etiologies (dog bite, hot oil burn, forehead trauma, and facial laser treatment complications) was treated with RSCEs in combination with microneedling (Dermapen 4.0, 0.2–0.4 mm depth) and/or thulium laser therapy (Lutronic Ultra MD, 8–14 J), or as a standalone topical treatment. All cases underwent sequential treatments over periods ranging from two to four months, with comprehensive photographic documentation of the progression. The efficacy was assessed through clinical photography and objective evaluation using the modified Vancouver Scar Scale (mVSS) and the Patient and Observer Scar Assessment Scale (POSAS), along with assessment of scar appearance, texture, and coloration. Results: All cases demonstrated progressive improvement throughout the treatment course. The dog bite scar showed significant objective improvement, with a 71% reduction in modified Vancouver Scar Scale score (from 7/13 to 2/13) and a 61% improvement in Patient and Observer Scar Assessment Scale scores after four combined treatments. The forehead trauma case exhibited similar outcomes, with a 71% improvement in mVSS score and 55–57% improvement in POSAS scores. The hot oil burn case displayed the most dramatic improvement, with a 78% reduction in mVSS score and over 70% improvement in POSAS scores, resulting in near-complete resolution without visible scarring. The facial laser complication case showed a 75% reduction in mVSS score and ~70% improvement in POSAS scores using only topical exosome application without device-based treatments. Clinical improvements across all cases included reduction in elevation, improved texture, decreased erythema, and better integration with surrounding skin. No adverse effects were reported in any of the cases. Conclusions: This preliminary case series suggests that plant-derived exosome-like nanoparticles, specifically rose stem cell exosomes (RSCEs), may enhance scar treatment outcomes when combined with microneedling and laser therapy, or even as a standalone topical treatment. The documented objective improvements, measured by standardized scar assessment scales, along with clinical enhancements in scar appearance, texture, and coloration across different scar etiologies—dog bite, burn, traumatic injury, and iatrogenic laser damage—suggest that this approach may offer a valuable addition to the current armamentarium of scar management strategies. Notably, the successful treatment of laser-induced complications using only topical exosome application demonstrates the versatility and potential of this therapeutic modality.

17 February 2025 in Life
Verified
Journal Article
Open access
PDF file
Lidia MajewskaLidia Majewska
Lidia Majewska
JKJacek Kijowski
Jacek Kijowski
KDKarolina Dorosz
Karolina Dorosz
Objective: This study aimed to establish a reproducible protocol for obtaining four plasma fractions (autologous platelet-rich plasma (C-PRP, PRP LCC) and platelet-rich fibrin (I-PRF, F-PRF)) from a single blood draw and to evaluate their effectiveness in enhancing skin density and thickness in facial aesthetic treatments across different age groups. Methodology: Twenty participants aged 30–60 years received three treatments at 4–6 week intervals, with C-PRP, PRP LCC, I-PRF, and F-PRF injections in targeted facial areas. Ultrasound measurements provided an objective method to assess the outcomes, and statistical analysis evaluated the changes in skin density and thickness. A comprehensive literature review contextualized our findings within the broader scientific discourse on PRP and PRF applications in aesthetic medicine. Results: The protocol successfully yielded four distinct plasma fractions from a single blood draw. Ultrasound and statistical analyses demonstrated significant improvements in skin density and thickness, particularly in the lower eyelid area. These improvements were consistent across all the age groups, suggesting that the therapy’s effectiveness is independent of age. The findings also align with previous research, underscoring PRP’s and PRF’s roles in stimulating fibroblast activity, promoting collagen synthesis, and enhancing skin quality.

1 January 2024 in Dermatologic Therapy
Verified
Journal Article
Open access
Lidia MajewskaLidia Majewska
Lidia Majewska
JKJacek Kijowski
Jacek Kijowski
KDKarolina Dorosz
Karolina Dorosz
Objective. This single‐center, prospective, open‐label randomized study aimed to produce a repeatable procedure for isolating platelet‐rich plasma (PRP), maximizing platelet recovery and concentration parameters from the collected material, and to assess the effectiveness of autologous platelet‐rich plasma (concentrated platelet rich plasma C‐PRP and platelet rich plasma low centrifugation concept PRP LCC) and platelet‐rich fibrin (injectable platelet rich fibrin I‐PRF and fluid platelet rich fibrin F‐PRF) injections on skin density and thickness in facial aesthetic treatments. Methods. Twenty participants aged 30–60 underwent a series of three treatments (intervals: 4–6 weeks). The study encompassed the following two stages: a laboratory and a clinical one. In the first stage, the aim was to optimize centrifugation parameters (time and speed) of whole blood to produce the highest quality product for use in aesthetic treatments. Double centrifugation of blood produced the following four types of plasma fractions with different parameters: platelet‐rich plasma (C‐PRP and PRP LCC) and platelet‐rich fibrin (I‐PRF and F‐PRF) each with two different platelet concentrations (202% in the first centrifugation and 148% in the second centrifugation). The total PLT recovery in the procedure was 76%, with an average of 32% in the first centrifugation and that of 44% in the second one. In the clinical stage, treatments involved C‐PRP, PRP LCC, I‐PRF, and F‐PRF injections in the forehead, lower eyelid, and cheek areas. In ultrasound skin examination with randomly assigned measurements for each patient, a series of acoustic density values directly proportional to tissue density was obtained. Thickness of the skin was also determined (µm) by summation of the epidermis and dermis thickness. Measurements were made in the lateral forehead, lower eyelids, and cheek regions. Results. Statistical analysis elucidates the effectiveness of blood‐derivatives therapy in the introduced regiment. The increase in skin density was statistically significant after the following treatment: three sessions in 4–6 week intervals, each consisting of 1 mL of C‐PRP injections in the forehead area, 1 mL of I‐PRF injections in the lower eyelid area, and 3.5 mL of PRP LCC and 3.5 mL of F‐PRF injections in the cheek area. Furthermore, significant improvements in skin density were recorded in the cheek and forehead areas (F(3, 24) = 4.5170 with p = 0.011971 for cheeks and F(3, 24) = 9.2327 with p = 0.000305 for forehead). Lower eyelid skin density and thickness also increased significantly (F(3, 24) = 3.2653, p = 0.038881). No significant changes were noted in skin thickness in the forehead and cheek areas (F(3, 6) = 1.438771, p = 0.321616 for cheeks; F(3, 6) = 2.383248, p = 0.168172 for forehead). Patient satisfaction was high, as evidenced by a GAIS average score of 2.75. Conclusion. The study confirms the efficacy of C‐PRP, PRP LCC and I‐PRF, and F‐PRF injections in increasing skin density and, to a lesser extent, skin thickness in specific facial areas. As a result of this research, ready‐to‐use kits (PLASMOO) for obtaining PRP and PRF were developed and put into production. These findings underscore the potential of autologous plasma and fibrin formulations in aesthetic medicine, which offer substantial improvements in skin quality and patient satisfaction. This trial is registered with ISRCTN10538865.

23 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Lidia MajewskaLidia Majewska
Lidia Majewska
KDKarolina Dorosz
Karolina Dorosz
JKJacek Kijowski
Jacek Kijowski
Patients undergoing epidermal growth factor receptor inhibitor (EGFRI) therapy frequently experience dermatologic side effects, notably papulopustular rash, which impacts 50–90% of recipients. This rash typically appears on the face, chest, and back within weeks of treatment, resembling acne but stemming from distinct pathophysiological mechanisms, causing significant discomfort and reduced quality of life. Prophylactic measures and symptom-based treatment are recommended, emphasizing patient education, topical agents, and systemic therapies for severe cases. A 41-year-old female with advanced colonic mucinous adenocarcinoma developed severe acneiform rash and pruritus during EGFRI therapy with panitumumab. Initial standard treatment with oral doxycycline was discontinued after two days due to severe gastrointestinal intolerance characterized by intense nausea and dyspepsia. With limited access to dermatological consultation, treatment with rose stem cell-derived exosomes (RSCEs) provided rapid symptom relief. Significant improvement was observed within 24 h, with complete resolution of pruritus and substantial reduction in inflammatory lesions within 72 h. RSCEs demonstrate anti-inflammatory effects through the modulation of pro-inflammatory cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α, while promoting fibroblast proliferation and collagen synthesis enhancement. They may represent a possible alternative to corticosteroids, avoiding associated side effects such as skin atrophy, delayed wound healing, and local immunosuppression. This case underscores the potential of innovative treatments like RSCEs in managing EGFRI-induced skin complications when standard therapies are not tolerated, particularly in healthcare systems with limited dermato-oncological resources.